Document is current
Any future updates will be listed below
-
Authors
Fathima, Parveen https://orcid.org/0000-0002-4516-4127
Jones, Mark https://orcid.org/0000-0003-1736-1702
D’Souza, Reena
Totterdell, James https://orcid.org/0000-0002-9459-2566
Andric, Nada
Abbott, Penelope https://orcid.org/0000-0003-4865-4823
Norman, Richard https://orcid.org/0000-0002-3112-3893
Howard, Kirsten
Cheng, Wendy
Pedrana, Alisa https://orcid.org/0000-0002-1998-5722
Doyle, Joseph S. https://orcid.org/0000-0001-7198-0833
Davies, Jane
Snelling, Thomas https://orcid.org/0000-0003-4670-0638
-
Funding
Funding for this research was provided by:
2020 Medical Research Future Fund - PPHR Initiative - Efficient use of existing medicines (2007164)
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 30 May 2024
First Online: 17 June 2024
Declarations
:
: This study was approved by the Sydney Local Health District Human Research Ethics committee (Ref: 2022/ETH0168).
: Not applicable as individual level data or potential identifying attributes will not be included in any published material. The participant information materials and informed consent forms are available from the authors on request.
: AP reports investigator-initiated funding to their institution from Gilead Sciences, AbbVie and Merck. AP also reports honoraria to their institution from Gilead Sciences. JSD has received research funding to his institution from Gilead Sciences and AbbVie, and honoraria from AbbVie to his institution. All other authors declare that they have no competing interests.
